

B<sup>3</sup>

5. (Amended) A composition according to claim 4, wherein the anti-fibrotic agents include antibodies to TGF $\beta$ -1, TGF $\beta$ -2 and PDGF; binding proteins which prevent TGF $\beta$ -1, TGF $\beta$ -2 and PDGF from binding to their receptors by either binding to the growth factor itself [, eg. Decorin, Biglycan,] or binding to the receptor, [eg. peptides containing the receptor site sequence]; or soluble forms of growth factor receptor or the growth factor binding domains of these receptors or antisense oligonucleotides or ribosymes which act to prevent fibrotic growth factors mRNA translation.

In claim 6, line 2, please delete "and/".

In claim 7, line 2, please delete "and/".

B<sup>4</sup>

20. (Amended) A composition according to claim 1, wherein said fibrotic growth factor[(s) comprises] is selected from the group consisting of TGF $\beta$ -1, [and/or] TGF $\beta$ -2, [and/or] PDGF, and mixtures of two or more thereof.

Please add the following new claims.

B<sup>5</sup>

21. A composition for use in the healing of wounds with no or at least reduced scarring as compared with healing by natural processes and for the treatment of fibrotic disorders, comprising (1) TGF $\beta$ -3 or a non-fibrotic fragment thereof with no fibrotic growth factor or (2) ~~at least one non-fibrotic growth factor selected from the group consisting of~~

D